Oncology

Pathology and Huvos Grading: Your Treatment "Report Card"

At a Glance

The Huvos grading system measures how much of an osteosarcoma tumor was killed by chemotherapy before surgery. A 'good response' is 90% or more tumor cell death (necrosis), which is associated with a better prognosis and lower risk of the cancer returning.

After surgery to remove an osteosarcoma, the most important piece of information your medical team receives is the pathology report. This document acts as a “report card” for the neoadjuvant chemotherapy (the treatment given before surgery). It tells your doctors exactly how the tumor responded to the drugs and provides a window into your child’s future prognosis ^[1]^[2].

The Huvos Grading System

The Huvos system is the gold standard for measuring how much of the tumor “died” because of the chemotherapy ^[3]. This process of cell death is called necrosis. The pathologist carefully examines the entire removed tumor to see what percentage of it is still “viable” (living) versus necrotic (dead) ^[3]^[4].

Huvos Grade	Percentage of Necrosis	Response Level
Grade I	0% – 50%	Poor
Grade II	51% – 89%	Poor
Grade III	90% – 99%	Good
Grade IV	100% (No living cells)	Good

Why 90% is the Magic Number

A “good histologic response” is defined as having 90% or more necrosis (Huvos Grades III and IV) ^[5]^[6]. Research shows that patients who reach this 90% threshold generally have a much better outlook and a lower risk of the cancer returning ^[1]^[4]. If the response is less than 90% (Grades I and II), your oncology team may discuss the best path forward, though research is ongoing about whether changing the chemotherapy drugs after a poor response significantly improves outcomes ^[7]^[8].

Decoding Your Pathology Report

Pathology reports can be full of technical jargon. Here are the most common terms you will encounter:

Tumor Necrosis: The percentage of cancer cells that were successfully killed by chemotherapy ^[3].
Malignant Osteoid: This is “immature bone” produced directly by the cancer cells; its presence confirms the diagnosis of osteosarcoma ^[9].
Margins: This describes the edge of the tissue the surgeon removed. Negative margins (or R0) mean no cancer cells were found at the very edge, indicating the tumor was likely removed in its entirety ^[10].
Pleomorphism: A term used to describe how abnormal the cells look under a microscope. High pleomorphism means the cells look very different from healthy bone cells ^[11].
Mitotic Rate: A measurement of how quickly the cancer cells are dividing. A high mitotic rate often points to a more aggressive tumor ^[12].
Skip Metastasis: A small, separate “island” of tumor located within the same bone but away from the main mass ^[13].

Pathology Report Completeness Checklist

To ensure your child’s care team has all the information they need, a complete pathology report should include the following details:

[ ] Histologic Subtype: (e.g., osteoblastic, chondroblastic, or telangiectatic) ^[2].
[ ] Tumor Size: The maximum length, width, and depth of the mass.
[ ] Huvos Grade/Necrosis Percentage: The exact percentage of dead tissue ^[3].
[ ] Surgical Margin Status: Whether cancer was found at the bone or soft tissue edges ^[2].
[ ] Skip Lesions: Confirmation that the rest of the bone was checked for separate tumor spots ^[13].
[ ] Vascular Invasion: Whether the cancer has begun to grow into nearby blood vessels.
[ ] Bone Penetration: Has the tumor broken through the cortex (the hard outer shell of the bone)? ^[14].

If any of these items are missing, you should feel empowered to ask your oncologist for a follow-up or a review by a dedicated musculoskeletal pathologist ^[2].

Common questions in this guide

What does the Huvos grade mean for osteosarcoma?

The Huvos grade measures the percentage of tumor cells that died (necrosis) due to chemotherapy given before surgery. Grades I and II indicate a poor response, while Grades III and IV indicate a good response.

Why is 90% tumor necrosis considered important?

Having 90% or more tumor necrosis means the cancer responded very well to chemotherapy. This is linked to a better long-term prognosis and a lower risk of the osteosarcoma returning.

What do negative margins mean on my child's pathology report?

Negative margins, also called R0, mean that no cancer cells were found at the very edge of the tissue removed during surgery. This indicates that the surgeon likely removed the entire tumor.

What are skip metastases in osteosarcoma?

A skip metastasis is a separate, smaller island of tumor cells found within the same bone but separated from the main tumor mass. Pathologists check for these to ensure all cancer is identified.

What does malignant osteoid mean?

Malignant osteoid is immature bone produced directly by cancer cells. Finding this immature bone under the microscope is what confirms the diagnosis of osteosarcoma.

Curated prompts to bring to your next appointment.

1.Does our child’s report show 90% or more tumor necrosis, and what does that mean for their next phase of chemotherapy?
2.Were all of the surgical margins reported as 'negative' or 'R0', and what does that tell us about the risk of the cancer returning in that spot?
3.Can you explain the specific histologic subtype (like osteoblastic or chondroblastic) and how that affects our child's prognosis?
4.Who was the bone pathologist who reviewed this specimen, and how often do they see osteosarcoma cases?
5.Does the presence of residual viable tumor cells mean we should consider a different chemotherapy protocol after surgery?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (14)

1
Clinico-pathological Study of Limb Salvage Surgery for Osteosarcoma: Experience in a Rural Cancer Center.
Vijayanarasimha D, Nayanar SK, Vikram S, et al.
Indian journal of surgical oncology 2017; (8(2)):136-141 doi:10.1007/s13193-016-0547-8.
PMID: 28546707
2
Multidisciplinary approach to osteosarcoma.
Biazzo A, De Paolis M
Acta orthopaedica Belgica 2016; (82(4)):690-698.
PMID: 29182106
3
Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study.
Prabowo Y, Setiawan I, Kamal AF, et al.
International journal of surgical oncology 2021; (2021()):8843325 doi:10.1155/2021/8843325.
PMID: 33996154
4
The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma.
Araki Y, Yamamoto N, Hayashi K, et al.
Scientific reports 2021; (11(1)):1989 doi:10.1038/s41598-020-80504-w.
PMID: 33479294
5
Response to neoadjuvant chemotherapy and survival of children and adolescents with high-grade osteosarcoma treated based on the EURAMOS-1 protocol.
Suárez-Mattos A, Arroyave F, Infante AM, et al.
Boletin medico del Hospital Infantil de Mexico 2022; (79(1)):17-25 doi:10.24875/BMHIM.21000087.
PMID: 35086129
6
Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.
Bishop MW, Chang YC, Krailo MD, et al.
Pediatric blood & cancer 2016; (63(10)):1737-43 doi:10.1002/pbc.26034.
PMID: 27128693
7
Risk-Based Therapy for Localized Osteosarcoma.
Venkatramani R, Murray J, Helman L, et al.
Pediatric blood & cancer 2016; (63(3)):412-7 doi:10.1002/pbc.25808.
PMID: 26501936
8
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma.
Park JA, Shin HY
Journal of pediatric hematology/oncology 2017; (39(5)):e270-e274 doi:10.1097/MPH.0000000000000802.
PMID: 28267080
9
The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I, Navarro S, Picci P, Llombart-Bosch A
Pathology, research and practice 2016; (212(9)):811-6.
PMID: 27465835
10
Salivary Gland Secretory Carcinoma: Clinicopathologic and Genetic Characteristics of 215 Cases and Proposal for a Grading System.
Baněčková M, Thompson LDR, Hyrcza MD, et al.
The American journal of surgical pathology 2023; (47(6)):661-677 doi:10.1097/PAS.0000000000002043.
PMID: 37070739
11
Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer.
Mercan C, Balkenhol M, Salgado R, et al.
NPJ breast cancer 2022; (8(1)):120 doi:10.1038/s41523-022-00488-w.
PMID: 36347887
12
Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors.
Xu B, Viswanathan K, Umrau K, et al.
Histopathology 2022; (81(5)):670-679 doi:10.1111/his.14772.
PMID: 35974431
13
The sensitivity, specificity, and diagnostic accuracy of whole-bone MRI for identifying skip metastases in appendicular osteosarcoma and Ewing sarcoma.
Barnett JR, Gikas P, Gerrand C, et al.
Skeletal radiology 2020; (49(6)):913-919 doi:10.1007/s00256-019-03364-0.
PMID: 31900513
14
Multimodal Imaging of Osteosarcoma: From First Diagnosis to Radiomics.
Cè M, Cellina M, Ueanukul T, et al.
Cancers 2025; (17(4)) doi:10.3390/cancers17040599.
PMID: 40002194

This information about osteosarcoma pathology and Huvos grading is for educational purposes only. Always discuss your child's specific pathology report with their pediatric oncologist.

Get notified when new evidence is published on Osteosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents